InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
Product | Citation | Year | Journal | Authors | Page |
---|---|---|---|---|---|
Ionomycin | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
Mouse Control IgG2a | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
2'3'-cGAMP | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
STING inhibitor | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
Recombinant human IFN-γ | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
G3-YSD | CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell... | 2024 | Cell Mol Immunol. | Lei X. et al. | DOI: 10.1038/s41423-024-01133-1 |
LPS-EB VacciGrade™ | Vitamin A deficiency impairs neutrophil-mediated control of Salmonella via SL... | 2024 | Nat Microbiol. | Lokken-Toyli K.L. et al. | DOI: 10.1038/s41564-024-01613-0 |
Normocin® - Antimicrobial Reagent | Single-cell and spatial multi-omics highlight effects of anti-integrin therap... | 2024 | Nat Commun. | Mennillo E. et al. | DOI: 10.1038/s41467-024-45665-6 |
ODN 1826 - TLR9 ligand | Reduction in creatine metabolites in macrophages exposed to small molecule an... | 2024 | Parasite Immunol. | Alanazi S. et al. | DOI: 10.1111/pim.13026 |
Primocin® | Interplay in galectin expression predicts patient outcomes in a spatially res... | 2024 | Biomed Pharmacother. | Abudu O. et al. | DOI: 10.1016/j.biopha.2024.116283 |
pFUSE2-CLIg-hK | ACE2-Fc and DPP4-Fc decoy receptors against SARS-CoV-2 and MERS-CoV variants:... | 2023 | Antib Ther. | Alfaleh M.A. et al. | DOI: 10.1093/abt/tbad030 |
Anti-hIL-6 Neutralizing mAb | Importance of IL-6 trans-signaling and high autocrine IL-6 production in huma... | 2024 | Osteoarthritis Cartilage | Eitner A. et al. | DOI: 10.1016/j.joca.2024.02.006 |
Plasmocin® - Mycoplasma Elimination Reagent | Molnupiravir inhibits human norovirus and rotavirus replication in 3D human i... | 2024 | Antiviral Res. | Santos-Ferreira N. et al. | DOI: 10.1016/j.antiviral.2024.105839 |
Puromycin | Nuclear RNA-related processes modulate the assembly of cytoplasmic RNA granules. | 2024 | Nucleic Acids Res. | Angel M. et al. | DOI: 10.1093/nar/gkae119 |
IFN-α/β Reporter B16 Cells | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
QUANTI-Blue™ | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
Zeocin® | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
Blasticidin | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
Normocin® - Antimicrobial Reagent | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |
IFN-α/β Reporter HEK 293 Cells | Increased type-I interferon level is associated with liver damage and fibrosi... | 2024 | Hepatol Commun. | Salzmann R.J.S. et al. | DOI: 10.1097/HC9.0000000000000380 |